標題名稱:
新刊~海馬最新發表文獻!
發佈日期:
2018-10-16
詳細內容:

尚博生物科技定期提供您使用"海馬"將能量代謝與各個研究領域結合的最新文章.

https://seahorseinfo.agilent.com/acton/fs/blocks/showLandingPage/a/10967/p/p-0189/t/page/fm/1

 

恭喜中研院與台大研究團隊使用海馬發表文獻

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
Hsu, W. T., Huang, C. Y., Yen, C. Y. T., Cheng, A. L. and Hsieh, P. C. H.
Theranostics. 2018 May 9, 8 (12):3176-3188.  
 

Publication of the Month

Seahorse provides functional confirmation of CRISPR and stem cell-cardiomyocyte workflow

Mosqueira, D., et al. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur Heart J. 2018.
 

Metabolic measurements offer significant potential for stem cell disease modeling with gene editing tools like CRISPR. Phenotyping is absolutely critical in a disease modeling workflow to confirm how a disease model is actually functioning. Although we all believe in our hearts that Agilent Cell Analysis provides a valuable solution, one of the biggest challenges has been the limited research examples demonstrating our applications. Stem cell disease modeling with gene editing tools like CRISPR is a relatively new area of research, and thus we seek to expand to include examples using these approaches that exemplify the value that Agilent Cell Analysis can bring.

The selected publication of the month is a solid example that nudges us (leaps and bounds!) in the right direction. The publication uses CRISPR/Cas9 gene editing to produce 11 isogenic genome-edited variants to model cardiac disease, based on 3 independent human pluripotent stem cell-cardiomyocyte lines (hPSC-CM). There was a positive correlation between metabolic measurements and mutation loads- in other words, mitochondrial respiration rates were perturbed in bMHC mutant hPSC-CMs. Seahorse XF provided functional measurements to support the main conclusions linking energy production and efficiency mechanisms to cardiac disease (Hypertrophic cardiomyopathy), and to help validate specific mutations associated with these disorders.

The study advances a mechanistic understanding of cardiac function that will be valuable in developing therapeutic treatments. In addition to these interesting findings, the golden ticket aspect of this publication was a fantastic workflow contextual diagram for disease modeling that highlights Seahorse within one of the 3 main workflow pillars: 1. Gene editing à 2. Cardiac differentiation à 3. PHENOTYPING!!! Check it out!